1. Clinical benefit from combination limb infusion and CTLA-4 blockade.
Clinical benefit from combination limb infusion and CTLA-4 blockade. A, Schema of the phase II clinical trial. B, Swimmer plot of all patients, showing responses in the melphalan-treated limb. C, PFS for patients, including the 2 patients who died prior to the evaluation point. D, Example of durable response both in and outside of the limb of the infusion. This patient had an unknown primary melanoma and presented with multiple subcutaneous nodules of the limb, with groin adenopathy, biopsy-proven lung metastasis, and thoracic adenopathy. Three years after limb infusion and systemic ipilimumab, the patient remains free of disease (bottom plot).
Charlotte E. Ariyan et al. Cancer Immunol Res 2018;6:
©2018 by American Association for Cancer Research